Congress Asset Management Co. Acquires 18,295 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Congress Asset Management Co. grew its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 2.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 709,316 shares of the medical instruments supplier's stock after acquiring an additional 18,295 shares during the period. Congress Asset Management Co. owned 3.16% of LeMaitre Vascular worth $65,888,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of LMAT. Conestoga Capital Advisors LLC grew its holdings in LeMaitre Vascular by 0.4% during the second quarter. Conestoga Capital Advisors LLC now owns 1,941,501 shares of the medical instruments supplier's stock valued at $159,747,000 after purchasing an additional 8,584 shares during the period. Vanguard Group Inc. grew its position in LeMaitre Vascular by 0.3% in the first quarter. Vanguard Group Inc. now owns 1,553,834 shares of the medical instruments supplier's stock valued at $103,112,000 after purchasing an additional 4,964 shares in the last quarter. Copeland Capital Management LLC lifted its stake in LeMaitre Vascular by 1.0% in the third quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier's stock valued at $108,068,000 after acquiring an additional 11,318 shares during the last quarter. Driehaus Capital Management LLC lifted its stake in LeMaitre Vascular by 52.2% in the second quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier's stock valued at $21,740,000 after acquiring an additional 90,573 shares during the last quarter. Finally, Summit Creek Advisors LLC lifted its stake in shares of LeMaitre Vascular by 0.6% during the 1st quarter. Summit Creek Advisors LLC now owns 229,936 shares of the medical instruments supplier's stock worth $15,259,000 after buying an additional 1,435 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Price Performance

NASDAQ LMAT traded down $0.66 on Thursday, reaching $88.39. 191,960 shares of the company's stock traded hands, compared to its average volume of 122,304. LeMaitre Vascular, Inc. has a 12 month low of $45.96 and a 12 month high of $93.32. The stock has a 50-day simple moving average of $89.48 and a 200 day simple moving average of $82.73. The stock has a market cap of $1.99 billion, a PE ratio of 52.93, a P/E/G ratio of 2.29 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The company had revenue of $55.85 million during the quarter, compared to analyst estimates of $54.98 million. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The firm's revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.37 earnings per share. As a group, analysts anticipate that LeMaitre Vascular, Inc. will post 1.86 EPS for the current year.

Insider Buying and Selling at LeMaitre Vascular

In related news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the sale, the director now directly owns 14,114 shares in the company, valued at approximately $1,158,335.98. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.79% of the company's stock.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Barrington Research reiterated an "outperform" rating and issued a $92.00 price objective on shares of LeMaitre Vascular in a research note on Friday, September 20th. StockNews.com lowered shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Tuesday, August 27th. Lake Street Capital started coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They set a "buy" rating and a $105.00 target price on the stock. JMP Securities boosted their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a "market outperform" rating in a research report on Tuesday, August 20th. Finally, Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a "neutral" rating and a $96.00 price target on the stock. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, LeMaitre Vascular has a consensus rating of "Moderate Buy" and a consensus price target of $94.67.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.